How Targeted Therapy Disrupts the Treatment Paradigm for Acquired TTP: The Risks, Benefits, and Unknowns.

Camila Masias; Additional authors and institutional affiliations; Camila Masias Castanon

How Targeted Therapy Disrupts the Treatment Paradigm for Acquired TTP: The Risks, Benefits, and Unknowns.

Camila Masias, Additional authors and institutional affiliations, Camila Masias Castanon

Research output: Contribution to journal › Article › peer-review

Abstract

Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.

Original language	American English
Journal	Blood
State	Published - Aug 1 2019

Disciplines

Medicine and Health Sciences

Cite this

@article{88878782e3004f2d97499a657a098eaa,

title = "How Targeted Therapy Disrupts the Treatment Paradigm for Acquired TTP: The Risks, Benefits, and Unknowns.",

abstract = " Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP. ",

author = "Camila Masias and \{and institutional affiliations\}, \{Additional authors\} and \{Masias Castanon\}, Camila",

note = "Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; ca ...",

year = "2019",

month = aug,

day = "1",

language = "American English",

journal = "Blood",

}

TY - JOUR

T1 - How Targeted Therapy Disrupts the Treatment Paradigm for Acquired TTP: The Risks, Benefits, and Unknowns.

AU - Masias, Camila

AU - and institutional affiliations, Additional authors

AU - Masias Castanon, Camila

N1 - Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; ca ...

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.

AB - Insights into immune-mediated thrombotic thrombocytopenic purpura (iTTP) pathophysiology have led to novel targeted therapies. Immunomodulatory strategies target anti-ADAMTS13 antibodies: rituximab is effective in inducing responses in refractory/relapsed TTP and increasing relapse-free survival; caplacizumab targets the von Willebrand factor-platelet interaction to hasten platelet count recovery and reduce mortality and TTP-related ischemic events. Bortezomib and recombinant ADAMTS13 are under investigation. This review examines how targeted therapies are disrupting current treatment paradigms to improve outcomes of iTTP.

UR - https://pubmed.ncbi.nlm.nih.gov/31217190/

M3 - Article

JO - Blood

JF - Blood

ER -

How Targeted Therapy Disrupts the Treatment Paradigm for Acquired TTP: The Risks, Benefits, and Unknowns.

Abstract

Disciplines

Other files and links

Cite this